BidaskClub Downgrades Medidata Solutions (MDSO) to Hold

BidaskClub cut shares of Medidata Solutions (NASDAQ:MDSO) from a buy rating to a hold rating in a report issued on Monday morning.

MDSO has been the topic of several other research reports. Royal Bank of Canada decreased their target price on Medidata Solutions to $91.00 and set an outperform rating on the stock in a research note on Tuesday, September 25th. Zacks Investment Research lowered Medidata Solutions from a hold rating to a sell rating in a research note on Tuesday, October 16th. ValuEngine raised Medidata Solutions from a hold rating to a buy rating in a research note on Thursday, November 1st. Piper Jaffray Companies decreased their target price on Medidata Solutions to $83.00 and set an overweight rating on the stock in a research note on Friday, January 4th. Finally, JPMorgan Chase & Co. decreased their target price on Medidata Solutions to $74.00 and set a neutral rating on the stock in a research note on Friday, October 19th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of $82.82.

Shares of Medidata Solutions stock traded down $0.69 during trading hours on Monday, hitting $67.79. The company’s stock had a trading volume of 6,119 shares, compared to its average volume of 484,631. Medidata Solutions has a twelve month low of $59.60 and a twelve month high of $88.87. The firm has a market cap of $4.13 billion, a PE ratio of 79.12, a price-to-earnings-growth ratio of 4.00 and a beta of 1.32. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.15.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 18th. The company reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.06. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The business had revenue of $163.41 million for the quarter, compared to analyst estimates of $162.09 million. During the same quarter in the prior year, the company posted $0.33 EPS. The company’s quarterly revenue was up 17.6% on a year-over-year basis. As a group, equities analysts expect that Medidata Solutions will post 0.85 earnings per share for the current year.

In other news, CFO Rouven Bergmann sold 10,000 shares of the stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the chief financial officer now owns 88,862 shares in the company, valued at approximately $6,664,650. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert Taylor sold 2,120 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $64.70, for a total value of $137,164.00. Following the completion of the transaction, the director now owns 41,916 shares in the company, valued at approximately $2,711,965.20. The disclosure for this sale can be found here. Insiders sold a total of 36,150 shares of company stock worth $2,676,186 in the last ninety days. 4.70% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zevenbergen Capital Investments LLC increased its holdings in shares of Medidata Solutions by 2.2% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 567,229 shares of the company’s stock valued at $45,696,000 after acquiring an additional 12,245 shares during the last quarter. AMP Capital Investors Ltd increased its holdings in shares of Medidata Solutions by 16.8% in the 3rd quarter. AMP Capital Investors Ltd now owns 53,310 shares of the company’s stock valued at $3,933,000 after acquiring an additional 7,670 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Medidata Solutions in the 3rd quarter valued at about $229,000. Rice Hall James & Associates LLC increased its holdings in shares of Medidata Solutions by 106.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 251,973 shares of the company’s stock valued at $18,472,000 after acquiring an additional 130,070 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Medidata Solutions by 3.0% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 34,464 shares of the company’s stock valued at $2,776,000 after acquiring an additional 993 shares during the last quarter.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Featured Article: What are different types of coverage ratios?

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply